Disclosed are 4-indol substituted 1-aminocyclohexane derivatives as represented by the general formula (I), wherein A represents N or CR7-10, wherein A represents N at most twice; W represents O, S or NR4 with the proviso that if W represents O or S, A denotes CR7-10; one of the radicals B or C represents H or optionally substituted alkyl; and the other radical B or C represents a 4-amino-4-(alkyl/phenyl or heteroaryl)-cyclohexyl derivative; and wherein the remaining substituents are as defined herein. Also disclosed are compounds such as 2-(4-(dimethylamino)-4-phenylcyclohex-1-enyl)-3-benzyl-1H-indole hydrochloride and 1-butyl-4-(5-fluoro-3-(2-(piperidin-1-yl)ethyl)-1H-indol-2-yl)-N,N-dimethyl-cyclohexanamine citrate. Further disclosed is a medicament which contains at least one compound as defined above, optionally in the form of a racemate, of pure stereoisomers, in the form of an acid or of a base or in the form of a salt, or in the form of a solvate, and optionally containing one or more additives and/or one or more auxiliary substances and/or one or more optionally further active compounds for the treatment of conditions such as stress, depression, epilepsy, Alzheimer's disease, senile dementia, catalepsy, general cognitive dysfunctions, learning and memory disorders, withdrawal symptoms, alcohol and/or drug and/or medicament abuse and/or dependency, sexual dysfunctions, cardiovascular diseases, hypotension, hypertension, tinnitus, pruritus, migraine, impaired hearing, lack of intestinal motility, impaired food intake, anorexia, obesity, locomotor disorders, diarrhoea etc.
4-INDOL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM